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Background: The aim of present meta-analysis was to evaluate the effectiveness of tranexamic acid (TXA) use in
reducing blood loss and the related thrombotic complications in spinal surgery.
Methods: Three databases (MEDLINE, EMBASE, and the Cochrane Library) were searched through October 2012 to
identify the relevant randomized controlled trials (RCTs) regarding the TXA effective in spinal surgery. Mean
differences (MDs) of blood loss, blood transfusions, and postoperative partial thromboplastic time (PTT), odds ratios
(ORs) of blood transfusion and thrombotic complication in TXA-treated group compared to placebo group were
extracted and combined using random-effect meta-analysis.
Results: A total of 6 RCTs comprising 411 patients were included in the meta-analysis according to the pre-defined
selection criteria. TXA-treated group had significantly less amount of blood loss and blood transfusions per patient,
and had smaller proportion of patients who required a blood transfusion compared with the placebo group. The
use of TXA can significantly reduce the postoperative PTT with weighted MD of −1.59 [(95% confidence interval
(CI):-3.07, −0.10] There is a null association between thrombosis complications and the use of TXA.
Conclusion: We conclude that the use of TXA in patients undergoing spinal surgery appears to be effective in
reducing the amount of blood loss, the volume of blood transfusion, the transfusion rate, and the postoperative
PTT. However, data were too limited for any conclusions regarding safety. More high-quality RCTs are required
before recommending the administered of TXA in spinal surgery.
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Given the complexity of spinal surgeries, bleeding will
be inevitably faced during spinal surgery. Many patients
have to receive allogeneic blood transfusion because of
excessive blood loss, which may result in immunologic
reactions or transmitting infections, even cause transfusion-
related acute lung injury [1,2]. Another concern with re-
gard to perioperative bleeding in spinal surgery is the risk
of spinal epidural hematoma formation, which might lead
to spinal cord or cauda equina compression [3]. Therefore,
reducing blood loss both intra- and postoperatively pre-
sents a challenge to the spine surgeon [4,5].* Correspondence: shenhxgk@126.com
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unless otherwise stated.Various strategies, such as controlled hypotensive anes-
thesia, the cell salvage system, fresh-frozen plasma and
cryoprecipitate, to reduce the intraoperative blood loss
during spinal surgery have been attempted. Tranexamic
acid (TXA) is a synthetic antifibrinolytic drug that com-
petitively blocks the lysine binding sites of plasminogen,
plasmin, and tissue plasminogen activator, thereby retard-
ing fibrinolysis and blood clot degradation. It can decrease
intra- and postoperative bleeding by acting on the fibrino-
lytic system theoretically [6]. It has been confirmed that
TXA use could play a role in reducing blood loss in car-
diac surgery and hip or knee arthroplasty [7,8], However,
the effectiveness of TXA used in spinal surgery was con-
troversial in several studies [9-13]. Thus, we conducted a
meta-analysis of randomized controlled trials (RCTs) to
evaluate the effectiveness of TXA for the reduction of
blood loss in spinal surgery.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Literature search
We comprehensively identified studies through search-
ing MEDLINE (PubMed), EMBASE, and the Cochrane
Library through October 2012 for all RCTs published in
English regarding the effective and safe of the TXA use
in spinal surgery were searched from three databases.
The reference lists of retrieved articles were also manual
scanned to locate additional relevant studies. The follow-
ing key words were used for search: tranexamic acid,
spine, spinal.
Inclusion and exclusion criteria
All RCTs about the TXA use in the spinal surgery were
performed. We systematically reviewed published studies
according to the following criteria: (1) randomized con-
trolled trials; (2) subjects were underwent spinal fusion
including cervical, thoracic and lumber spine and adoles-
cent scoliosis correction surgery irrespective of anterior or
posterior approach; (3) the intervention was TXA intra-
venous(IV) administered an experimental group that used
TXA, a control group that received a placebo, intravenous
administration at the beginning of surgery in both groups,
and (4) the primary outcome measures should include one
of the following outcomes: amount of total blood loss,
amount of allogeneic blood transfusion, ratio of blood
transfusion and thrombosis complications, such as deep
vein thrombosis (DVT) or pulmonary embolism.
Studies should be excluded if they: 1) were nonrando-
mized controlled clinical trials; 2) had a low quality;
3) they had no interventions described above; 4) had a
non-intravenous administration drug; and 5) did not con-
tain any of the above outcomes.
Literature retrieve and quality assessment
Two investigators independently reviewed all titles, ab-
stracts, and the full text of articles that were potentially
eligible based on abstract review. Then the eligible trials
were selected according to the inclusion criteria. Disagree-
ment was resolved by discussion if necessary, or by involv-
ing a third reviewer for adjudication. We assessed the
study quality using the method described by Jadad et al.
[14], in which a study was judged on 3 aspects as follows:
1) random assignment (full score = 2); 2) blinding investi-
gators and patients (full score = 2), and 3) the proportion
of dropouts and withdrawals in the follow-up study (full
score = 1) Thus the full was 5 points. Studies with 3 points
or higher were considered to represent high-quality re-
search and were included in the meta-analysis.
Statistical analysis
For eligible studies, relevant data was extracted by two
investigators independently, including the data about the
amount of blood loss, the amount of allogeneic bloodtransfusion, the ratio of blood transfusion and DVT or
other thromboembolism, partial thromboplastic time
(PTT), thromboembolic complications, and any other
outcomes as mentioned in included studies. Of 6 in-
cluded RCTs [15-20], all studies reported the mean dif-
ferences (MDs) between TXA and placebo group for the
total blood loss and the amount of blood transfusion per
patient; all studies reported the odds ratio (OR) of blood
transfusion in TXA-treated group compared to placebo
group (referent); four studies [15-18] reported MD for
postoperative partial thromboplastic time (PTT); two
studies [15,18] reported MD for PTT at 24 h postopera-
tive; whereas only one study [17] reported the OR of
thrombotic complication for TXA. Therefore we se-
lected OR of blood transfusion for the use of TXA, and
MDs between TXA and placebo group for the total
blood loss, the amount of blood transfusion per patient,
postoperative PTT, and PTT at 24 h postoperative as the
effects of intervention. Statistical analysis were con-
ducted using Review Manager (RevMan) version 5.0
(The Cochrane Library, Oxford, United Kingdom). For
the amount of blood loss, the amount of blood transfu-
sion, PTT, the weighted mean differences with a 95%
confidence intervals (CIs) were combined in the meta-
analysis; while for the rate of patients needing transfu-
sion, the incidence of deep-vein thrombosis, and the rate
of pulmonary embolism, odds ratios (ORs) with 95% CIs
were combined. All the pooled analysis used random-
effect models. Heterogeneity across studies was detected
using Cochran’s Q and I2 statistics.
Results
Study selection and involved studies’ characteristics
Figure 1 summarizes the process for identifying eligible
studies. The search strategy yielded a total of 172 cita-
tions, of which 105 were eliminated on the basis of the
title review. TXA and spine were involved in 67 studies,
while only 9 had a RCT design. After full text review of
remaining 9 studies, one studies was excluded because
TXA in this study is not via intravenous administration;
one study was excluded because it used the different
control method, in which epsilon aminocaproic acid was
used in control group. At last, six RCTs [15-20] involv-
ing 411 patients were included in the final analysis, with
individual sample sizes ranging from 40 to 147 patients
(Table 1). The quality scores of the included studies were
above 4 points according the Jadad’s scoring-system. The
characteristics of included studies were presented in
Table 2. Two studies [15,16] is about correction surgery,
in which patients aged 8 to 18 year with either primary
or secondary scoliosis, one study focused on posterior
approach, and another focused on both anterior and
posterior approach, and part of the patients accepted the
autologous bone harvest procedure. Two studies [17,18]
Figure 1 Study selection process. A flowchart was present in this figure and the flowchart summarizes the selection of studies including
numbers and reasons of studies excluded.
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decompression and instrumented fusion; Two studies
[19,20] were about cervical spinal surgery, one focused
on laminoplasty only, and another one focused on anter-
ior cervical discectomy and laminectomy. No significant
differences in the baseline information was observed be-
tween the TXA and placebo groups, including the pa-
tient’s age, sex, height, weight, and hemoglobin. Blood
transfusion were undertaken if the hemoglobin was less
than 10 g/L in Farrokhi’s study [18] which was higher
than the others. The TXA was given as a loading dose
administered intravenously at the start of surgery in all
studies, followed by maintenance dose during the sur-
gery in 5 studies, only initiation dose of TXA was given
in Tsutsumimoto’s study [20]. Different doses and time
of delivery of TXA were used. Four studies used rela-
tively lower a dosage of TXA which ranged from 10 to
15 mg/kg, whereas 2 used a relatively higher dosage of




Male (TXA/P) Female (TX
Neilipovitz DT, 2001 [15] 22/18 17 (12/5) 23 (10/13)
Sethna NF, 2005 [16] 23/21 30 (17/13) 14 (6/8)
Wong J, 2008 [17] 73/74 47 (21/26) 100 (52/48)
Elwatidy S, 2008 [19] 32/32 39 (21/18) 25 (11/14)
Farrokhi MR, 2011 [18] 38/38 18 (11/7) 58 (27/31)
Tsutsumimoto T, 2011 [20] 20/20 31 (16/15) 9 (4/5)
Pts, patients; TXA/P, tranexamic acid group/placebo group.Amount of blood loss
Data on total blood loss were available in all six studies.
Our analysis showed perioperative intravenous adminis-
tration of TXA can significantly reduce the total blood
loss with MD of −100.68 ml (95% CI: −142.00 ml to
−59.36 ml) compared to placebo groups. Since the index
of I2 is 62%, some clinical heterogeneity were consid-
ered. In order to observe the potential source of such a
heterogeneity, subgroup analysis by surgical methods,
surgical approach and IV TXA dosage were conducted.
First, subgroup analysis was performed according to the
surgical methods. The amount of blood loss per patient
significantly decreased with MDs of 681.81 ml (95% CI:
214.49 to 1149.12 ml) and 96.10 ml (95% CI: 54.62 to
137.59 ml) in the TXA scoliosis subgroup and TXA non
scoliosis subgroup respectively, and the value of I2 de-
creased by 24% and 48% respectively (Figure 2). Second,
subgroup analysis by surgical approach and IV TXA dose
were performed, the amount of blood loss per patient-analysis
Age Weight
A/P) TXA Placebo TXA Placebo
14.1 ± 2.1 13.7 ± 2.5 41.8 ± 16.7 50.6 ± 20.2
13.6 ± 1.8 14.0 ± 2.0 59.4 ± 18.3 52.4 ± 15.7
56.8 ± 16.2 50.0 ± 16.2 72.9 ± 17.2 73.9 ± 16.1
51.56 ± 19.08 49.75 ± 21.04 72.48 ± 13.81 69.63 ± 17.29
45.5 ± 11.6 51.4 ± 11.6 66.6 ± 9.9 66.9 ± 9.4
68.0 ± 11.0 65.8 ± 11.8 59.6 ± 8.3 61.3 ± 10.2
Table 2 Characteristics of included studies






RCT I: 10 mg/kg Posterior spinal fusion for scoliosis,
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RCT I: 2 g for adouts,
30 mg/kg
for children
Eighteen pts had multiple level
anterior cervical discectomy with
or without fixation, 37 had spinal
decompression for multisegment
spinal stenosis, 9 had laminectomy













RCT I: 10 mg/kg Posterior thoracic or lumbar
instrumented spinal fusion









RCT I: 15 mg/kg Cervical laminoplasty from
C3 to C6
Blood loss, Hb,
Hct, PT, PTT, DVT,
hematoma formation
0 Not mention 4
P: Saline
Pts, patients; I, initiation dose of tranexamic acid; M, maintenance dose of tranexamic acid; P, placebo; Hb, hemoglobin; Plt, platelets; Hct, hematocrit; PT, prothrombin
time; PTT, partial thromboplastin time; MI, myocardial infarction; DVT, deep venous thrombosis.
Figure 2 The average amount of blood loss was significantly less in the TXA group compared with the placebo group (weighted mean
difference, −100.68 ml [95% CI, −142.00 to −59.36 ml]; p < 0.00001); similar result in the scoliosis sub group (weighted mean difference,
−681.81 ml [95% CI, −1149.12 to −214.49 ml]; p = 0.004) and non-scoliosis subgroup (weighted mean difference, −96.10 ml [95% CI,
−137.59 to −54.62 ml]; p < 0.00001;). TXA = tranexamic acid, SD = standard deviation, IV = inverse variance, and df = degrees of freedom.
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Figure 3 The average amount of blood loss was significantly less in the TXA group, either in subgroup of anterior-posterior approach
with high TXA dose or in subgroup of posterior approach with low TXA dose (weighted mean difference, −550.81 ml [95% CI, −873.51
to −228.11 ml]; p = 0.0008; weighted mean difference, −93.18 ml [95% CI, −134.84 to −51.52 ml]; p < 0.0001 respectively;). TXA = tranexamic
acid, SD = standard deviation, IV = inverse variance, and df = degrees of freedom.
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from 228.11 to 873.51 ml) and 93.18 ml (ranging from
51.52 to 134.84 ml) for the anterior-posterior approach with
high dose TXA subgroup and for the posterior approach
with low dose TXA subgroup respectively, and the value
of I2 decreased by 43% and 19% respectively (Figure 3).
Amount of blood transfusion
The number of patients requiring transfusion after sur-
gery was available in all six studies. The pooled weighted
MD for the amount of blood transfusion per patient be-
tween TXA group and placebo group is −234.61 ml (95%Figure 4 The amount of blood transfusion was significantly less in th
difference, −234.61 ml [95% CI, −383.23 to −85.99 ml]; p = 0.002). TXA
df = degrees of freedom.CI: −383.23 to −85.99 ml) (Figure 4). However, there was
significant heterogeneity within the selected studies.
Odds ratio of blood transfusion
The incidence of blood transfusion were provided in all
six studies. The TXA use could decreased 44% risk of
blood transfusion compared with the placebo group with
a OR of 0.56 (95% CI: 0.36 to 0.87) (Figure 5).
Odds ratio of thrombotic complication
Only one study reported the outcome of thrombotic
complications, and yielded a null association betweene TXA group compared with the placebo group (weighted mean
= tranexamic acid, SD = standard deviation, IV = inverse variance, and
Figure 5 The ratio of patients who accepted the blood transfusion was significantly less in the TXA group compared with the placebo
group (weighted mean difference, 0.56 [95% CI, 0.36 to 0.87]; p = 0.01). TXA = tranexamic acid, SD = standard deviation, IV = inverse variance,
and df = degrees of freedom.
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OR of 0.99 (95% CI: 0.06 to 16.07) (Figure 6).
Postoperative partial thromboplastic time
The outcome measure of PTT at the end of surgery was
available in four studies. The postoperative PTT was sig-
nificantly shorter in the TXA group compared with the
placebo group (weighted MD = −1.59 [95% CI, −3.07 to
−0.10]; p = 0.04) (Figure 7), however, the average values
of PTT in the four studies were vary from 34.4 to 45, all
of them were in the normal range (Figure 7). In addition,
the outcome of PTT at 24 h postoperative was available
in two studies. There was no significant difference for
postoperative PTT between the TXA group and the pla-
cebo group with weighted MD of −0.51 (95% CI, −2.71
to 1.68), p = 0.65) (Figure 8).
Discussion
This meta-analysis identified 6 RCTs that compared
TXA and placebo intravenous administration in spinal
surgery, and showed that the intravenous use of TXA inFigure 6 One patient (1/73) developed an asymptomatic non-Q myoc
DVT in the placebo group, it seems insignificant difference for the th
TXA = tranexamic acid, SD = standard deviation, IV = inverse variance, and dspinal surgery can significantly reduce the total blood
loss, the amount of blood transfusion, and the number
of patients needing transfusion; none of the patients in
the TXA-treated group had DVT or myocardial infrac-
tion, although the PTT was shorter at the end of surgery
in the TXA group. These results are similar to the meta-
analysis about TXA used in total knee arthroplasty and
coronary artery bypass graft surgery [7,21].
Gill’s meta-analysis [22] regarding the use of antifibri-
nolytic agents in spine surgery also demonstrated that
antifibrinolytic drugs could reduce the amount of blood
loss and blood transfusion in spinal surgery, however,
the included literatures were not all RCT studies, and
thrombotic complications were not considered. Our
meta-analysis revealed that the use of TXA in patients
who was performed spinal surgery can also reduce the
total blood loss. These results are similar to previous
clinical trials [23,24]. However, because the significant
heterogeneity existed within included studies, our find-
ings should be interpreted with cautions. We hypothe-
sized that surgical methods, surgical approach, and TXAardial infarction in the TXA group and one patient (1/74) had a
rombolic complications between the TXA and placebo group.
f = degrees of freedom.
Figure 7 The postoperative partial thromboplastin time was significantly less in the TXA group compared with the placebo group
(weighted mean difference, −1.59 [95% CI, −3.07 to −0.10]; p = 0.04). TXA = tranexamic acid, SD = standard deviation, IV = inverse variance,
and df = degrees of freedom.
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was confirmed by our subgroup analysis. For surgical
methods, the patients who received scoliosis correction
were teenagers, they were younger, less weight, and had
more surgery involved levels and larger wound area. The
number of level fused ranged from 7 to 18 in Neilipovitz’s
study [15], some patients accepted anterior soft tissue re-
lease and posterior spinal instrumentation concurrently in
Sethna’s study [16]. In contrast, there were 2 to 6 vertebrae
involved in the surgery procedure. Indeed, heterogeneity
was reduced although did not eliminate completely after
subgroup analysis (Scoliosis subgroup, I2 = 24%, P = 0.25;
Non scoliosis subgroup, I2 = 48%, P = 0.13). Similar results
were obtained from the subgroup analysis by surgical ap-
proach and TXA dose. Different anatomical structures will
be dissected and injured in different surgical approach,
accompanied with different blood loss. Eighteen patients
accepted multilevel anterior cervical discectomy, twelve
patients accepted laminectomy and discectomy, and
others accepted laminectomy in Eiwatidy’s study [19],
eight patients accepted lateral thoracotomy or a thoraco-
scopic procedure and posterior instrumentation concur-
rently in Sethna’s study [16]. TXA dose may be another
resource of heterogeneity, It was difficult to distinguish
due to the high dose TXA was administered in the two
studies. Moreover, operating time was also known as an
important factor influencing the blood loss, it ranged from
89 min to 420 min averagely in these 6 RCTs, according
to the experience, longer operating time with more bloodFigure 8 The outcome of partial thromboplastin time at 24 h postope
group (weighted mean difference, −0.51 [95% CI, −2.71 to 1.68]; p = 0
variance, and df = degrees of freedom.loss, anything could influence the blood loss by changing
the operating time. Spinal surgery procedures are complex
and diversity, blood loss could be effected by many factors.
However, the blood loss was significantly decreased in
each subgroup with TXA administered. TXA may benefit
blood loss reduction in spinal surgery from the exiting
data, more powerful evidence was needed in the future.
Our meta-analysis also manifested that the use of
TXA significantly reduced the amount of blood transfu-
sions and the rate of patients requiring transfusion when
compared with the placebo group. The number of pa-
tients requiring transfusion and the amount of blood
transfusion were influenced by many factors, such as the
amount of blood loss and the indication of transfusion.
Blood transfusion was undertaken when the hemoglobin
was less than 10 g/L in Farrokhi’s study [18], much
higher than the others. We speculated the difference of
transfusion threshold may be the reason of heterogen-
eity, the postulation were supported because the value of
I2 decreased to 0 when excluded the study. According to
the final statistic outcome, the amount of blood transfu-
sion decreased with use of TXA for patients undergoing
spinal surgery and fewer patients required blood transfu-
sion. Of these six studies, the amount of blood loss
decreased to 25-49% [17,19], the amount of blood trans-
fusion decreased to 28-80% [15,19]. The risk of related
complication such as immunologic reactions and viral
transmission might reduce followed the decrease of blood
transfusion.rative was similar between the TXA group and the placebo
.65). TXA = tranexamic acid, SD = standard deviation, IV = inverse
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gery perioperative has been the focus of the spine sur-
geon [25,26]. More data may be needed to access the
safety of TXA used in spine surgery because there were
few studies about the issue. A meta-analysis about the
TXA used in cardiac surgery showed that the complica-
tion such as stroke and myocardial infraction did not in-
crease in the TXA group [27]. In our meta-analysis, the
thrombotic complication was reported only in Wong’s
study, one patient (1/73, 1.37%) developed an asymp-
tomatic non-Q myocardial infarction in the TXA group
and one patient (1/74, 1.35%) had a DVT in the placebo
group. It seems insignificant difference for the throm-
bolic complications between the TXA and placebo
group. However, the numbers of patients in both groups
were small, and larger numbers of patients in samples of
randomized controlled trials are needed to support the
results. More important, patients were assessed daily for
any DVT in 2 studies [15,18], no special investigations
for DVT in other studies. More studies specifically
screened for thromboembolism may offer more confi-
dence for TXA administered in spinal surgery. Available
data were too limited for any conclusions regarding
safety.
TXA inhibits fibrinolysis and consequently stabilizes
the fibrin clots [28]. The PTT may be affected by the
TXA because of its affect the fibrinolysis system. Some
authors [19] found no significant difference in PTT be-
tween the TXA and the placebo group. In our meta-
analysis, the PTT was significantly less in the TXA
group at the end of surgery, while similar between the
two groups at 24 h postoperatively. However, the average
values of PTT in the four studies were varies from 34.4
to 45, all of them were in the normal range, there was
statistically significant but clinically small difference. We
cannot conclude that PTT had been affected by the
TXA. Further studies are needed to evaluate the change
of PTT after TXA used.
There are some potential limitations in our meta-
analysis. Because we only selected literature published in
English, and searched through MEDLINE, PubMed,
EMBASE, and the Cochrane Database, articles written in
other languages or included in other database may have
been missed, thus the publication bias could not be
ruled out. The second limitation was that the difference
existed among the methods of spine surgery, which may
lead to the heterogeneity and affect the reliability of our
study.
Conclusions
In conclusion, the use of TXA in patients undergoing
spinal surgery appears to be effective in reducing the
amount of blood loss, the volume of blood transfusion
and the transfusion rate. However, data were too limitedto reach any conclusions regarding safety of intravenous
use of TXA. More high-quality randomized controlled
trials are required before applying the administered of
TXA in spinal surgery to support the conclusion.
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